The Medullary Thyroid Carcinoma (MTC) Registry Consortium* is partnering with the American Thyroid Association® (ATA) to create a registry (list) of all new cases of MTC diagnosed in the United States over the next 10-15 years (the MTC Registry).


Pharmaceutical company Takeda has announced the recall of the its parathyroid hormone for injection, NATPRA.


To assist endocrinologists and their support staff, AACE Practice Management has gathered the latest updates in QPP, MACRA and more. For more information, please e-mail practicemanagement@aace.com.


The Government Accountability Office (GAO) has released a new study on prescription drug use to treat obesity.

Several physician members of American Association of Clinical Endocrinologists (AACE) — including Dr. W. Timothy Garvey, Dr. Ken Fuijoka, and Dr. Ania Jastreboff — participated in the study’s development and report.


The CDC recently launched in collaboration with Google Health, a prediabetes quiz that will pop up when end users search for certain medical information using their Google browser to bring more public awareness about prediabetes.


Medicare imposed substantial cuts in reimbursements for the new and revised fine needle aspiration codes for 2019. AACE, together with the Endocrine Society and American Thyroid Association, advocated for you with letters to Centers for Medicare and Medicaid Services (CMS) and Congress opposing these cuts. We secured a win with the release of the proposed physician pay rule issued July 29. 


In this webinar, attorneys Robert Liles and Paul Weidenfeld will discuss EKRA, the Anti-Kickback Statue and State All Payor Rules along with steps your practice should take to stay out of trouble. This webinar is scheduled for 60 minutes with a Q and A session to follow.


Join Liles Parker Attorneys Leonard Schneider and Jennifer Papapanagiotou for this webinar, scheduled for 60 minutes with a Q & A session to follow. Registration is free.


Use the tools to assist obese patients from diagnosis to treatment and management.
Use the url below to link to the tool kit.

Nutrition and Obesity toolkit


August 1, 2019

Commercial Carrier Update

AACE Practice Management has gathered the latest news from commercial carriers to help endocrinologists and their practices. For more information, please e-mail practicemanagement@aace.com.


To help assist endocrinologists and staff, AACE Practice Management has gathered the latest about compliance, audits and areas of risk for your practice. For more information, please e-mail practicemanagement@aace.com.


AACE Practice Management has gathered the latest information for correct coding, coverage determinations and prior authorizations to help in the management of your practice. Take advantage of coding and billing webinars throughout the year from AACE partners Practice Management Institute (PMI) and Liles Parker: click here to learn more. For more information, please e-mail practicemanagement@aace.com.


AACE Practice Management has gathered the latest news from the Centers of Medicare & Medicaid Services to help endocrinologists and their practices. For more information, please e-mail practicemanagement@aace.com.


The Centers for Medicare & Medicaid Services (CMS) issued a proposed rule that includes proposals to update payment policies, payment rates, and quality provisions for services furnished under the Medicare Physician Fee Schedule (PFS) on or after January 1, 2020.


The nomination period is NOW OPEN for the 2020 AACE/ACE Awards. AACE Members may nominate colleagues to recognize the extraordinary accomplishments and exceptional contributions of leaders in our field.


Medscape reports the nasal powder, used in the treatment of severe hypoglycemia for patients aged 4 years or older, is the first licensed glucagon product that is not delivered by injection and that does not require a multistep mixing process.


The FACE application period is from Monday, August 12, 2019, 8:00 am ET to Friday, November 01, 2019, 5:00 pm, ET. FACE Applications for 2020 will only be accepted through an online process.


Prasad, M. et al. Triglyceride and Triglyceride/HDL (High Density Lipoprotein) Ratio Predict Major Adverse Cardiovascular Outcomes in Women With Non-Obstructive Coronary Artery Disease. J Am Heart Assoc. 2019;8:e009442. DOI: 10.1161/JAHA.118.009442.)


Chait, A. and Eckel, R. The Chylomicronemia Syndrome Is Most Often Multifactorial. Ann Intern Med. 2019;170:626-634. doi:10.7326/M19-0203


Arnett DK, Blumenthal RS, Albert MA et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation 2019:Cir0000000000000678


Hawley CE, et al. Statins for Primary Prevention in Those Aged 70 Years and Older: A Critical Review of Recent Cholesterol Guidelines. Drugs Aging 2019


Kim DW, et al. Association between statin treatment and new-onset diabetes mellitus: a population based case-control study. Diabetology & metabolic syndrome 2019; 11:30


Schleyer T, Hui S, Wang J, et al. Quantifying unmet need in statin-treated hyperlipidemia patients and the potential benefit of further LDL-C reduction through an EHR-based retrospective cohort study. J Manag Care Spec Pharm. 2019;25(5):544-554. 


Presenting PrescriptionHelp.aace.com – A directory of prescription affordability programs and resources for your endocrine patients to help them acquire the medications they need at reduced out-of-pocket costs.


In the systematic review and meta-analysis of more than 4,000 patients with adenomas published in the Annals of Internal Medicine (Elhassan et al), authors reported that patients with mild autonomous cortisol secretion or nonfunctioning adrenal adenomas very rarely develop overt hormonal excess (<0.1%). In addition, adenoma growth >1cm occurred only in 2.5% of patients and no patient developed an adrenal malignancy at follow up.


The U.S. Food and Drug Administration is warning patients and health care providers that certain Medtronic MiniMed insulin pumps are being recalled due to potential cybersecurity risks.


The QPP Submissions API will only accept requests and return responses in QPP JSON format. This means that files must be uploaded to the QPP website in either QPP JSON or QRDA III XML.


The Centers for Medicare & Medicaid Services (CMS) has contracted with Guidehouse to conduct data validation and audits of a select number of Merit-based Incentive Payment System (MIPS) eligible clinicians. Data validation and audits are processes that will help ensure MIPS is operating with accurate and useful data. MIPS eligible clinicians, groups and virtual groups are required by regulation to comply with data sharing requests, providing all data as requested by CMS.


JUNE 18–19, 2019 | 1:00-3:30 pm ET | These interactive training webinars by the Centers for Medicare & Medicaid Services are stand-alone events covering Medicare Program basics. You aren’t required to attend both days, and space is limited.


When it comes to optimal bone health and fracture prevention, there is scant evidence for recommending supplementation with vitamins and minerals other than calcium and vitamin D, according to AACE member Daniel L. Hurley, MD, FACE, who spoke at the AACE 28th Annual Scientific & Clinical Congress.


This year, at the 28th Annual Scientific & Clinical Congress, AACE made changes to the traditional lecture format and pushed for casual presentations, allowing more in-depth and interactive conversations. Read about the change from a member's perspective in this editorial by Archana Sadhu, MD, FACE, longtime Los Angeles resident.


Findings presented at the AACE 28th Annual Scientific & Clinical Congress showed that seeking hospital care for diabetic ketoacidosis during the weekend as opposed to during the week may increase mortality risk.


The Centers for Medicare and Medicaid Services (CMS) has posted the following new resources to the Quality Payment Program (QPP) Resource Library, including the 2019 MIPS Eligibility Decision Tree, specialty guides, and eligibility redetermination fact sheet.


The Centers for Medicare & Medicaid Services (CMS) issued a Request for Information (RFI) seeking new ideas from the public on how to continue the progress of the Patients over Paperwork initiative. Since launching in fall 2017, Patients over Paperwork has streamlined regulations to significantly cut the “red tape” that weighs down our healthcare system and takes clinicians away from their primary mission—caring for patients. 


The Quality Payment Program (QPP) is creating more ways for developers to build software that integrates directly with CMS applications and data. As part of that initiative, the Quality Payment Program Developer Tools now includes information on how to programmatically interact with eligibility data via the Eligibility Application Programming Interface (API).


Type 2 diabetes (T2D) is associated with increased risk for fractures in the short term but not in the long term, according to study results presented at the AACE 28th Annual Scientific & Clinical Congress.


Treatment with linagliptin in patients with type 2 diabetes (T2D) and cardiovascular and/or kidney disease had no impact on risk for cardiovascular or kidney events or hospitalization for heart failure, according to results of the CARMELINA study (Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus) presented at the AACE 28th Annual Scientific & Clinic


Abaloparatide followed by alendronate treatment may improve bone mineral density (BMD) in women with postmenopausal osteoporosis and type 2 diabetes (T2D), according to study results presented at the AACE 28th Annual Scientific & Clinical Congress. 


The use of an insulin pump to deliver continuous pulsatile cortisol may be a viable treatment option in patients with severe adrenal insufficiency who are unresponsive to oral corticosteroids, according to study results presented at the AACE 28th Annual Scientific & Clinical Congress. 


Biochemical markers and clinical signs and symptoms of endogenous Cushing syndrome improved after 6 months of levoketoconazole therapy, according to phase 3 study results presented at the AACE 28th Annual Scientific & Clinical Congress. 


Significantly more euthyroid patients with thyroid disease suffer from anxiety compared with depression, regardless of whether they have Hashimoto thyroiditis autoimmunity, according to research results presented at the AACE 28th Annual Scientific & Clinical Congress. 


A weighted cardiometabolic disease staging risk score can be used to quantify race- and sex-specific type 2 diabetes risk in a large, diverse population, according to study results presented at the AACE 28th Annual Scientific & Clinical Congress. 


Hypothyroidism is a risk factor for increased length of hospital stay and mortality in patients with congestive heart failure (CHF), according to study results presented at the AACE 28th Annual Scientific & Clinical Congress.


Teprotumumab effectively reduces proptosis in patients with active thyroid eye disease, according to phase 3 confirmatory trial data presented at the AACE 28th Annual Scientific & Clinical Congress.


For indeterminate thyroid nodules following fine needle aspiration, evidence of thick post-microcystic reflection on ultrasound was found to be associated with malignant nodules, according to study results presented at the AACE 28th Annual Scientific & Clinical Congress.


Lower income and education levels may negatively affect the experience and expectations of patients who are obese who receive care for weight management, according to study results presented at the AACE 28th Annual Scientific & Clinical Congress.


The cardiovascular and renal effects of treatment with canagliflozin in patients with type 2 diabetes are more prominent in patients not taking metformin compared with patients treated with canagliflozin as an add-on to metformin, according to data from the CANVAS (CANagliflozin cardioVascular Assessment Study) Program presented at the AACE 28th Annual Scientific & Clinical Congress.


Endocrine Today has compiled a list of the top five news stories posted from the American Association of Clinical Endocrinologists Scientific & Clinical Congress, held April 24-28, 2019, in Los Angeles.


Distinctive serum steroid profiles might emerge in patients with adrenal tumors and Cushing's syndrome, according to research reported by Shobana Athimulam, MBBS, of the Mayo Clinic in Rochester, Minnesota, and colleagues, at the AACE 28th Annual Scientific & Clinical Congress.


The ThyroSeq v3 Genomic Classifier was able to effectively classify thyroid nodules with samples collected through fine needle aspiration (FNA), according to research reported by Lindsey Tolino, MBA, of the University of Pittsburgh Medical Center in Pennsylvania, and colleagues, at the AACE 28th Annual Scientific & Clinical Congress.


The investigational agent teprotumumab was effective for reducing proptosis associated with thyroid eye disease, according to late-breaking phase III data presented by Raymond Douglas, MD, PhD, of Cedars Sinai Medical Center in Los Angeles, and colleagues, at the AACE 28th Annual Scientific & Clinical Congress.


The investigational agent relacorilant significantly improved excess cortisol in patients with endogenous hypercortisolism, researchers reported at the AACE 28th Annual Scientific & Clinical Congress.


Among patients on hemodialysis, trabecular bone score was helpful in predicting fracture risk, researchers reported during an oral presentation of the findings at AACE’s 28th Annual Scientific & Clinical Congress.


AACE Member Roy Taylor, MD, discussed the pathogenesis of hepatic insulin resistance in people with type 2 diabetes in an interview at AACE’s 28th Annual Scientific & Clinical Congress.


AACE Member Felicia Cosman, MD, professor of medicine at Columbia University, New York, discussed the current state of osteoporosis treatment in an interview at AACE’s 28th Annual Scientific & Clinical Congress.


Lewis E. Braverman, MD, MACE, 89, passed away peacefully on Monday, June 10, 2019. He leaves his wife Mimi Braverman; his sons, William Braverman and Daniel Braverman; and his five grandchildren.


CR 11003 introduced the enrollment process for the providers who intend to get their Additional Documentation Request (ADR) letters electronically (as eMDR) through their registered Health Information Handler. Make sure your billing staffs are aware of these changes.


Kevin Pho, MD, is a board-certified internal medicine physician and founder of KevinMD, social media’s leading physician voice. He has been named the web’s top social media influencer in health care and medicine. Dr. Pho is coming to AACE to deliver the keynote address “Social Media and the Physician” on Saturday, April 27. AACE2019News.com recently had the opportunity to ask Dr. Pho a few questions about his presentation, social media and why endocrinologists should get on the social media train.


Bhatt DL, Steg G, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380:11-22.

https://www.nejm.org/doi/full/10.1056/NEJMoa1812792


Treatment of hypercholesterolemia with statins results in significant reductions in cardiovascular risk; however, individuals with well-controlled low-density lipoprotein cholesterol (LDL-C) levels, but persistent high triglycerides (TG), remain at increased risk.


Shin J, Chung JW, Jang HS et al. Achieved low-density lipoprotein cholesterol level and stroke risk: A meta-analysis of 23 randomised trials. Eur J Prev Cardiol 2019:2047487319830503.

http://www.ncbi.nlm.nih.gov/pubmed/?term=30782002


Fogacci F, Banach M, Mikhailidis DP et al. Safety of Red Yeast Rice Supplementation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pharmacol Res. 2019; 143:1-16.

http://www.ncbi.nlm.nih.gov/pubmed/?term=30844537


Ference BA, Ray KK, Catapano AL, et al. Mendelian Randomization Study of ACLY and Cardiovascular Disease.


Ray KK, Bays HE, Catapano AL, et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med. 2019;380:1022-1032.

https://www.nejm.org/doi/full/10.1056/NEJMoa1803917


An estimated 30.3 million Americans have type 2 diabetes (T2D), a complex, progressive disease that requires intensified treatment over time.1-3 The complexity of T2D management, coupled with the need to tailor treatment recommendations to individual patients, presents an ongoing clinical challenge. The number and variety of treatment options available for T2D has increased dramatically in the last 15 years, with several new drug classes emerging as safe and effective.2,4,5


A preliminary slate of candidates for the election of Officer positions for a one-year (1) term, five (5) open positions on the Board of Directors for election to a three-year (3) term (2019-2022) and one (1) open position on the Board of Directors for a one-year (1) term (2019-2020) to fill the unexpired term of Dr. Sethu Reddy, who was elected Secretary in 2018, was sent to the membership via email/fax on December 28.


Horizon Reimbursement Policies effective February 25, 2019 will be applied to professional claims for services provided to patients enrolled in fully insured groups and ASO groups that opted in to policy guidelines. Diabetic screening services, duplicate claim logic for independent lab services, lab services billed by physicians are just a few of the policies that may affect endocrinologists. We strongly encourage you to review the content of each policy.

2019 Training Materials for Part D Opioid Policies.